Please login to the form below

Not currently logged in

Santhera CEO Klaus Schollmeier joins SuppreMol

He has experience at ING BHF-Bank, BASF, Knoll and Abbott

Santhera CEO Klaus Schollmeier joins SuppreMolFormer CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO.

Dr Schollmeier (pictured right) had served as CEO of Santhera since its formation in 2004, and was appointed chairman in October 2011.

He has both senior scientific and business experience, previously serving as managing director healthcare-biotechnology at ING BHF-Bank; head of oncology-immunology research at BASF; and general manager for BASF's operations in Western Europe.

Prior to his time at BASF, he held senior roles at Knoll and Abbott.

In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires.

Dr Thomas Hecht, chairman of the company's advisory board, paid tribute to Prof Buckell for his “long-standing commitment” as he welcomed Dr Schollmeier.

He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical development with important clinical and regulatory milestones ahead. Dr Schollmeier will bring the necessary experience to the company to advance SuppreMol's products towards a Biologics License Application.”

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

5th April 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...